Teva VP Ika Abravanel resigns
CEO Avner Halperin: Our objective is to take our product to market, beginning in the US and Europe.
Patient monitor developer EarlySense Ltd. has raised $13 million in its third financing round. Pitango Venture Capital led the round, joined by the company's current investors, Challenge Fund - Etgar, ProSeed Venture Capital Fund (TASE:PRSD), Docor International Management Ltd., Noaber Foundation, and Bridge Investment Fund.. The start-up recently completed trials and regulatory procedures, and is now preparing for sales, for which the proceeds of the financing will be used.
EarlySense co-founder and CEO Avner Halperin told "Globes", "Our objective is very sharply focused - to take our product, with the successful results of the trials, and bring it to market. We'll being in the US and Europe. We will set up a team, which we believe will begin generating sales in the second half of the year."
EarlySense's EverOn monitor and patient managing system monitors patients who are not in intensive care. The system includes a plasma screen, which the company installs in wards and at nurses' stations to provide information about the condition of patients, without disturbing their privacy.
EverOn is installed underneath a hospital bed mattress. There are no leads or cuffs to connect to the patient, who has complete freedom of movement and is not burdened by any irritating attachments. The system measures patient vital signs and movements and alerts medical personnel of the changes in a patient’s condition. EverOn detects heart and respiration rates, bed entries and exits, as well as patient movement.
Halperin said, "We obtained US Food and Drug Administration (FDA) approval, and positive results at a number of sites. The system works and meets a technical and clinical need." EarlySense has raised $24 million to date. ProSeed invested $750,000 in the current round and will also convert $556,000 in loans to shares, boosting its stake in the company to 5.7%.
"Globes": Who needs the system?
Halperin: "Currently in both the US and Israel, 80% of hospitalizations in emergency care and cardiology wards are not monitored. In the coming years, regulatory changes are expected, which will require hospitals to monitor general patients as well. The condition of general patients has worsened, and monitoring can help treat them better. No less importantly, it can save hospitals many expenses."
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.